Abcam given a shot in the arm by Goldman Sachs


Shares in Abcam (LON:ABC), which manufactures antibodies used in clinical research, were given a shot in the arm by Goldman Sachs.

Placing the Abcam on its ‘conviction buy’ list, the American investment bank said there was the potential for the stock to climb over 50% in the next six months. Its price target of 645p reflects this.

“We believe Abcam can continue to grow ahead of the broader consumable life science tools market through share gains and a shift towards more technologically advanced products, where it has a high share and which contribute a higher gross margin,” said analyst Carl Hazeley.

“The company’s proprietary data asset that grows through user-generated content should drive attachment and reliance on its products. 

“This, in turn, should support a positive pricing dynamic. We forecast significant cash generation owing to Abcam’s capitallight business model, and expect cash to be deployed towards bolt-on acquisitions and special dividends.”

The shares, off 12% in the year to date, rose 1.5% to 431p.

Quick facts: Abcam

Price: 1340.5 GBX

Market: AIM
Market Cap: £2.76 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



ROBO Global team discuss its focus on innovation and key developments in AI

ROBO Global's director of research Jeremie Capron and strategic adviser Wyatt Newman discuss the firm's focus on technology innovation and the importance of taking a longer-term view when it comes to its investments. They also discuss what they consider to be some of the key upcoming...

1 hour, 26 minutes ago

2 min read